1. Home
  2. AVBP vs ULCC Comparison

AVBP vs ULCC Comparison

Compare AVBP & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVBP
  • ULCC
  • Stock Information
  • Founded
  • AVBP 2021
  • ULCC 1994
  • Country
  • AVBP United States
  • ULCC United States
  • Employees
  • AVBP N/A
  • ULCC N/A
  • Industry
  • AVBP
  • ULCC Air Freight/Delivery Services
  • Sector
  • AVBP
  • ULCC Consumer Discretionary
  • Exchange
  • AVBP NYSE
  • ULCC Nasdaq
  • Market Cap
  • AVBP 617.4M
  • ULCC 719.5M
  • IPO Year
  • AVBP 2024
  • ULCC 2021
  • Fundamental
  • Price
  • AVBP $20.15
  • ULCC $3.88
  • Analyst Decision
  • AVBP Strong Buy
  • ULCC Hold
  • Analyst Count
  • AVBP 6
  • ULCC 11
  • Target Price
  • AVBP $39.00
  • ULCC $5.67
  • AVG Volume (30 Days)
  • AVBP 162.5K
  • ULCC 4.8M
  • Earning Date
  • AVBP 05-20-2025
  • ULCC 05-01-2025
  • Dividend Yield
  • AVBP N/A
  • ULCC N/A
  • EPS Growth
  • AVBP N/A
  • ULCC N/A
  • EPS
  • AVBP N/A
  • ULCC 0.30
  • Revenue
  • AVBP N/A
  • ULCC $3,822,000,000.00
  • Revenue This Year
  • AVBP $63.13
  • ULCC $9.75
  • Revenue Next Year
  • AVBP N/A
  • ULCC $12.72
  • P/E Ratio
  • AVBP N/A
  • ULCC $13.07
  • Revenue Growth
  • AVBP N/A
  • ULCC 5.99
  • 52 Week Low
  • AVBP $15.47
  • ULCC $2.79
  • 52 Week High
  • AVBP $36.37
  • ULCC $10.26
  • Technical
  • Relative Strength Index (RSI)
  • AVBP 51.13
  • ULCC 53.27
  • Support Level
  • AVBP $18.84
  • ULCC $2.97
  • Resistance Level
  • AVBP $21.79
  • ULCC $3.68
  • Average True Range (ATR)
  • AVBP 1.12
  • ULCC 0.25
  • MACD
  • AVBP 0.00
  • ULCC 0.18
  • Stochastic Oscillator
  • AVBP 44.50
  • ULCC 96.58

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

About ULCC Frontier Group Holdings Inc.

Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.

Share on Social Networks: